An evaluation of odronextamab for the treatment of multiple subtypes of relapsed/refractory B-cell non-Hodgkin lymphoma
- Author(s)
- Bayly-McCredie, E; Prince, HM; Yannakou, CK; Fiorenza, S;
- Journal Title
- Expert Opinion on Biological Therapy
- Publication Type
- Online publication before print
- Abstract
- INTRODUCTION: Patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) have a poor median survival rate when treated with traditional salvage therapies. Bispecific antibodies (BsAbs) are an emerging class of 'off-the-shelf' immunotherapies that show promising efficacy in this population. Odronextamab is a CD20×CD3 targeting bispecific antibody that is being investigated in multiple subtypes of relapsed/refractory B-NHL. AREAS COVERED: This article describes the development of odronextamab from pre-clinical work through to ongoing clinical trials in relapsed/refractory B-NHL. The structure, safety, efficacy, and administration of odronextamab are discussed. Studies were selected for inclusion by performing a search in PubMed, EMBASE, Cochrane Library, and relevant conference abstracts from 2014 to 2024. The clinicaltrials.gov website and reference lists of the included studies were also reviewed. EXPERT OPINION: Odronextamab has demonstrated manageable safety and promising efficacy in multiple subtypes of relapsed/refractory B-NHL. The low rates of immune effector cell-associated neurotoxicity syndrome (ICANS) and high response rates in rare aggressive subtypes of B-NHL are particularly noteworthy. High rates of severe infections remain a challenge with BsAbs, with further prophylactic efforts required to reduce the risk. Clinical trials of combination therapies with odronextamab are required to improve the utility of this BsAb across a wider range of settings and subtypes of B-NHL.
- Keywords
- Cd20×cd3; bispecific antibody; diffuse large B-cell lymphoma; follicular lymphoma; odronextamab; relapsed/refractory B-cell non-Hodgkin lymphoma
- Department(s)
- Haematology
- Publisher's Version
- https://doi.org/10.1080/14712598.2025.2479631
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-03-27 06:21:34
Last Modified: 2025-03-27 06:22:10